volume 8, issue 10, Pe78330 2013
DOI: 10.1371/journal.pone.0078330
View full text
Has correction Has correction 2014-02-28Has erratum
|
Sign up to set email alerts
|
Share

Abstract: BackgroundMyocardial fibrosis is a key process in diabetic cardiomyopathy. However, their underlying mechanisms have not been elucidated, leading to a lack of therapy. The glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, reduces hyperglycemia but may also trigger direct effects on the heart.MethodsGoto-Kakizaki (GK) rats developed type-II diabetes and received sitagliptin, an anti-hyperglycemic drug (metformin) or vehicle (n=10, each). After cardiac structure and function assessment, plasma and left vent…

Expand abstract
Editorial notices

Search citation statements

Order By: Relevance

Citation Types

4
72
1

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals